The Georgia Cancer Center Grand Rounds series features talks on mature cancer-related basic, translational, clinical, or population, prevention, and control research projects.
This series is expected to raise awareness of the great work being done within the Georgia Cancer Center and potentiate expanded interactions and collaborations with colleagues, not just from within the Georgia Cancer Center but from the entire university as well as other institutions.
Our weekly Research in Progress seminar series is a forum for our faculty to present current research from their laboratories. Research areas include basic science/translational, clinical, and behavioral/prevention science related to cancer. The research presented can be at any stage of development, including the earliest stages, where the background and hypotheses are strong, but data are incomplete. The purpose of these talks is to stimulate discussion, generate constructive feedback, and initiate collaboration.
The Medical College of Georgia at Augusta University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Medical College of Georgia at Augusta University designates this live activity for a maximum of [number of credits] AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
|July 1, 2020||Joseph M. Miano, PhD||J. Harold Harrison, MD, Distinguished University Chair in Vascular Biology||Augusta University||Vascular Biology Center (AU) CRISPR Technology|
|July 8, 2020||Lauren Byers, MD, MS||Associate Professor / Physician Scientist, Department of Thoracic and Head and Neck Medical Oncology||MD Anderson Cancer Center||Intratumoral Heterogeneity in Lung Cancer - Dissecting Drug Resistance|
|July 15, 2020||Andrew Futreal BS, PhD||Department Chair, Department of Genomic Medicine, Division of Cancer Medicine||MD Anderson Cancer Center||Cancer heterogeneity – Challenges and Opportunities|
|July 22, 2020||Charles Sawyers, MD||Chair, Human Oncology and Pathogenesis Program||Memorial Sloan Kettering Cancer Center||Lineage Plasticity and Cancer Drug Resistance|
|July 29, 2020||James Allison, PhD||Chair, Department of Immunology, Division of Basic Science Research||MD Anderson Cancer Center||Immune Checkpoint Blockade in Cancer Therapy; New Insights into Therapeutic Mechanisms|
|August 5, 2020||John C. Hardaway, MD, PhD||Surgical Oncologist||Doctors Hospital of Augusta||Regional Delivery of CAR-T; Strategies for Solid Tumor Immunotherapy|
|August 12, 2020||Daniel de Carvalho, PhD||Canada Research Chair, Cancer Epigenetics||Princess Margaret Cancer Centre||Basic and Translational Aspects of Cancer Epigenetics – From Therapy to Liquid Biopsies|
|August 19, 2020||Gary A. Piazza, PhD||Chief, Drug Discovery Research Center and Abraham A. Mitchell Distinguished Investigator, Professor of Oncologic Sciences and Pharmacology||Mitchell Cancer Institute||Novel RAS inhibitor class: a few unanswered questions|
|August 26, 2020||Walter J. Curran, Jr., MD, FACR, FASCO||Executive Director||Winship Cancer Institute||Cancer Care and Research in the Time of COVID|
|Sept. 2, 2020||Jean-Pierre Issa, MD||President and Chief Executive Officer||Coriell Institute for Medical Research||Next Generation Epigenetic Therapy|
|Sept. 9, 2020||Yan Cui, PhD||Professor, Biochemistry and Molecular Biology||Georgia Cancer Center||CD73: a Pivotal Immune Checkpoint in the Tumor Microenvironment|
|Sept. 16, 2020||Keshav K. Singh, PhD||Director, Cancer Genetics Program||University of Alabama Comprehensive Cancer Center||Mito-Nuclear Cross Talk Underlying Cancer|
|Sept. 23, 2020||Paulo Rodriguez, PhD||Associate Member||Moffitt Cancer Center||Restoring Protective Anti-tumor Immunity by targeting central mediators of Myeloid and T cell function|
|Sept. 30, 2020||Wendy Bollag, PhD, FAHA||Professor of Physiology, VA Research Career Scientist||Medical College of Georgia||Phosphatidylglycerol-containing Surfaxin: A Possible Treatment for COVID-19 Pulmonary Failure?|
|October 7, 2020||Theodore S. Johnson, MD, PhD||Associate Professor, Cancer Immunology, Inflammation & Tolerance||Georgia Cancer Center||IDO-based Multimodal Immuno-radio-chemotherapy for Pediatric Brain Cancer|
|October 14, 2020||Vivian Wai Yan Lui, PhD||Associate Professor||Chinese University of Hong Kong||Translational Genomics and Immonogenomics of Head and Neck Cancer|
|October 21, 2020||Kenneth C. Anderson, MD||Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics||Dana-Farber Cancer Institute||Novel Therapies Targeting Myeloma in the Bone Marrow Microenvironment|
|October 28, 2020||Roni Bollag, MD, PhD||Director, Georgia Cancer Center Biorepository||Georgia Cancer Center||Georgia Cancer Center Biorepository and the statewide Biobankinginitiative (BRAG-Onc) in 2020|
|November 4, 2020||Chunhong Yan, PhD||Member, Molecular Oncology and Biomarkers Program
||Georgia Cancer Center||Regulation of Metabolic Stress Response by a Common Stress Sensor|
|November 11, 2020||Asamoah Bosomtwi, PhD||Director, MRI Imaging, Georgia Cancer Center Small Animal Imaging Shared Resource||Georgia Cancer Center||Quantitative and Qualitative Preclinical Imaging Capabilities at Georgia Cancer Center|
|November 18, 2020||Anatolij Horuzsko, MD, PhD||Professor, Biochemistry and Molecular Biology||Georgia Cancer Center||TREM1 is a potential target for the treatment of liver diseases|
|December 2, 2020||Oliver Bogler, PhD||Director, Center for Cancer Training||National Cancer Institute||Funding for Cancer Research Training from the NCI|
|December 9, 2020||Harikrishna Nakshatri, PhD||Marian J. Morrison Professor of Breast Cancer Research||Indiana University||Impact of genetic ancestry on normal breast heterogeneity and breast cancer biology|
|December 16, 2020||Dongfang Liu, PHD, MBBS||Associate Professor, Department of Pathology, Immunology &Laboratory Medicine, Center for Immunity and Inflammation||New Jersey Medical School, Rutgers University||Natural Killer Cells: from basic immunobiology to clinical application|
|January 6, 2021||Lei Zheng, M.D., Ph.D.||Co-Director, Pancreatic Cancer Precision Medicine Center of Excellence Program||Johns Hopkins Medicine||Rationale Behind the Clinical Development of Combination Immunotherapy for Pancreatic Cancer|
|January 13, 2021||Andrew W. Truman, PhD||Assistant Professor, Department of Biological Sciences||University of North Carolina at Charlotte||"Understanding Hsp70 interactions: new ways to
deal with difficult clients in cancer"
|January 20, 2021||Douglas Spitz, PhD||Director, Free Radical and Radiation Biology Program||University of Iowa Health Care||“Targeting Redox Metabolism for Cancer Therapy: From the Bench to the Bedside”|
|January 27, 2021||Besim Ogretmen, PhD||Endowed Chair, SmartState Endowed Chair in Lipidomics and Drug Discovery||Medical University of South Carolina||"Sphingolipid metabolism and signaling in cancer therapeutics: Implications in aging, neurodegeneration and immunotherapy"|
|February 3, 2021||Huidong Shi, PhD||Professor, Biochemistry and Molecular Biology||Georgia Cancer Center||"Epigenomics and Single Cell Sequencing Identifies Transcriptional Regulatory Networks That Control Resistance to Exhaustion and Antitumor Activity of CAR-T Cells"|
|February 10, 2021||Gideon E. Bollag, Ph.D.||Chief Executive Officer||Plexxikon||“Structure Guided Strategies to Optimize Cancer Therapies”|
|February 17, 2021||Ming Luo, PhD||Professor, Department of Chemistry||Georgia State University||"Armed Oncolytic Virus for Cancer Treatment"|
|February 24, 2021||Deyu Fang, MD/PhD||Hosmer Allen Johnson Professor of Pathology||Feinberg School of Medicine, Northwestern University||"Sirt1 in immune regulation, inflammation and cancer: a tale of red wine"|
|March 3, 2021||John W Henson, MD||Professor, Department of Neurology||Georgia Cancer Center||“Genetics and Precision Approaches in Neuro-oncology”|